Welcome to LookChem.com Sign In|Join Free

CAS

  • or

862718-31-8

Post Buying Request

862718-31-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

862718-31-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 862718-31-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,2,7,1 and 8 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 862718-31:
(8*8)+(7*6)+(6*2)+(5*7)+(4*1)+(3*8)+(2*3)+(1*1)=188
188 % 10 = 8
So 862718-31-8 is a valid CAS Registry Number.

862718-31-8Downstream Products

862718-31-8Relevant articles and documents

Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents

Liu, Hanfang,Ma, Jing,Li, Yingguang,Yue, Kexin,Li, Linrong,Xi, Zhuoqing,Zhang, Xiao,Liu, Jianing,Feng, Kai,Ma, Qi,Liu, Sitong,Guo, Shudi,Wang, Peng George,Wang, Chaojie,Xie, Songqiang

, p. 11324 - 11334 (2019)

Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We herein report that homospermidineplatin (4a), a polyamine-Pt(IV) prodrug, can potently inhibit tumor growth in situ and reverse cisplatin resistance as expected, and more importantly, 4a displays remarkably elevated antimetastatic activity in vivo (65.7%), compared to those of cisplatin (27.0%) and oxaliplatin (19.6%). The underlying molecular mechanism indicates that in addition to targeting nuclear DNA, 4a can modulate polyamine metabolism and function in a manner different from that of cisplatin. By upregulating SSAT and PAO, 4a downregulates the concentrations of Put, Spd, and Spm, which favors the suppression of fast-growing tumor cells. Moreover, the p53/SSAT/β-catenin and PAO/ROS/GSH/GSH-Px pathways are involved in the inhibition of 4a-induced tumor metastasis. Our study implies a promising strategy for the design of platinum drugs for the treatment of terminal cancer.

NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS

-

Page/Page column 104-105, (2010/02/13)

The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 862718-31-8